The Otricathâ„¢ introduces a new perspective on therapy delivery. The platform technology delivers cancer-fighting agents to solid tumors with unparalleled control, predictability, and safety for optimal therapeutic benefit and minimal systemic toxicity.

The Device

Pilot Studies

The Procedure



NHC, LLC | 2450 Holcombe Blvd., Suite X | Houston, TX 77021

713.839.8600 |